To review the current literature regarding the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS. Review of recently published (1990)(1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009) Keywords: erectile dysfunction; benign prostatic hyperplasia; lower urinary tract symptoms; LUTS; ED
Introduction
Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are highly prevalent in aging males, with a substantial impact on quality of life (QOL). Multiple studies have shown a strong association between these two entities, independent of other risk factors. This relationship may be explained by four interrelated theories: the nitric oxide/cyclic guanosine monophosphate pathway (NO/cGMP), the Rho-kinase pathway, autonomic hyperactivity (AH), and pelvic atherosclerosis. Clinical trials have shown that phosphodiesterase-5 (PDE5)-inhibitor treatment results in significant improvement in LUTS. The exact mechanism of action is not well understood. The results of these studies indicate that PDE5-inhibitor treatment has a role in treating LUTS in the setting of ED. Furthermore, PDE5-inhibitor therapy may expand to treat not only men with ED and/or LUTS, but also LUTS in women.
Background
BPH is a well-recognized clinical entity comprising enlargement of prostatic glandular tissue, concomitant narrowing of the urethra, with the subsequent development of LUTS. LUTS involves dysfunction of bladder storage or emptying, and consists of irritative and obstructive voiding symptoms. Irritative symptoms encompass increased urinary frequency, nocturia, and urgency. Obstructive symptoms include a weak or intermittent urinary stream, straining during evacuation, and incomplete bladder emptying. The incidence of BPH increases with age, such that it is seen in 50% of men over 50 years old, and increases to 90% in men over 80 years old. It has been shown that up to 50% of men with histologic evidence of BPH experience LUTS. [1] [2] [3] In addition, as men age, clinically significant BPH lesions become increasingly common. The Baltimore Longitudinal Study, a prospective examination of 1057 healthy males over 30 years of age, showed that the clinical diagnosis of LUTS matched the autopsy prevalence of BPH from 26% seen in 50 years old to 79% in 80 years old. 4 These findings were also seen in the Olmsted County Study, in which randomly selected males aged 40-79 years found moderate to severe LUTS increased with age from 26% in men 40-49 years old to 46% in men 70-79 years old. 5 ED, or the inability to obtain and/or maintain an erection suitable for sexual intercourse, also increases in prevalence as men age. The Massachusetts Male Aging Study showed that 52% of men between 40 and 70 years of age experienced some level of ED, from 39% in men in their 40s to 67% in men in their 70s. 6 Combined, these symptoms have been shown to have a substantial impact on patients' QOL, leading to disruption of daily activity.
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Epidemiologic data
A mounting body of epidemiologic data exists showing that LUTS and sexual dysfunction are inter-related clinical entities. Lukacs et al.
11 surveyed a cohort of 6000 males with LUTS and found that a patient's sexual dysfunction was related to both age and LUTS severity. In a cohort of 2476 Spanish men, Martin-Morales et al. 12 found that the prevalence of ED increased from 8.5% in men 35-39 years old to 48% in men 60-70 years old, as assessed by the International Index of Erectile Function (IIEF). Furthermore, LUTS was found to be the strongest independent risk factor for ED, with an age-adjusted odds ratio (95% confidence interval) of 2.67 (1.48-4.80) . The Cologne Male Survey, examining 5000 German men aged 30-80 years, found that the prevalence of LUTS in men with ED was 72.2% vs 37.7% in men without ED symptoms. After logistic regression analysis, LUTS was again confirmed to be an independent risk factor for ED. 13 The Multinational Survey of the Aging Male, a large study involving about 12 000 men in the United States and Europe, found that sexual dysfunction was strongly related to the severity of LUTS independent of other contributing factors. 14 These epidemiologic studies show a clear connection between LUTS and ED; however, a causal relationship has yet to be elucidated. Four possible pathophysiologic theories that involve smooth muscle contraction and prove this association are the nitric oxide synthase (NOS)/NO theory, the AH and metabolic syndrome theory, the Rho-kinase activation pathway, and pelvic atherosclerosis.
NOS/NO theory
A plausible link involves the NO/cGMP pathway. The role of NO/cGMP in corpus cavernosal smooth muscle relaxation is well understood. Immediate relaxation of cavernosal tissue is induced by neurogenic NO, whereas endothelial NO is involved in maintenance of relaxation. 15 Increased levels of NO lead to increases in cGMP production through guanylyl cyclase activity. cGMP subsequently phophorylates several other targets, leading to depletion of intracellular calcium. 16 This leads to a dissociation of calmodulin from myosin light chain (MLC) kinase and its inactivation (phosphorylation). Myosin is subsequently dephosphorylated by MLC phosphatase, detaching from actin. This cascade ultimately results in smooth muscle relaxation. 17 The inactivation of cGMP is mediated by phophodiesterases (PDEs).
Further studies have shown the presence of NO and PDEs in the remainder of the lower urinary tract, including the prostate, bladder, and urethra. Through inhibition of neurotransmission in the urethra and bladder afferent nerves, NO may also be involved in the micturition process. 18 NO has also been found to be involved in prostatic smooth muscle tone, glandular secretion, and blood flow. 19, 20 The distribution of various isoforms of NOS has been shown in prostatic tissue through immunohistologic means. Burnett et al. 21 have shown the presence of neurogenic NOS in nerve tissue in the prostate's transition zone. Studies by Richter et al. 22 and Bloch et al. 23 detected endothelial NOS in the vascular supply of the prostate and neurogenic NOS in the nerve fibers of the fibromuscular stroma, respectively. Gradini et al. 24 through immunohistochemical and polymerase chain reaction analysis showed expression of endothelial NOS in normal and hyperplastic prostatic tissue, whereas neurogenic NOS was prevalent in the secretory layer of glandular epithelium.
Bloch et al. 23 found NOS/NO levels to be decreased in the prostate's transition zone when comparing hyperplastic to normal tissue. Furthermore, nitrinergic innervation is decreased in hyperplastic prostatic tissue. These findings were confirmed by mRNA analysis of NOS gene levels in prostatic specimens extracted from TURP specimens from patients with BPH compared with normal prostatic tissue. There was a positive correlation between the decline in NOS level in relation to age and increased prostate volume. 25 Thus, it can be postulated that decreased nitrinergic innervation in BPH coupled with a reduction in NO-mediated smooth muscle relaxation may have a function in the pathophysiology of LUTS.
The presence of PDE5 within corpus cavernosum smooth muscle is well established. However, various isoforms of PDEs have also been found distributed throughout the lower urinary tract. Uckert et al. 26 showed the presence of multiple isoforms of PDEs within the transition zone of the prostate using polymerase chain reaction techniques. PDE4 was found in highest abundance, followed by PDE5. Specifically, PDE4 was present in the prostate's fibromuscular stroma, as well as the glandular tissue of the transition zone. Furthermore, the authors showed that sildenafil could mediate relaxation of prostatic transition zone tissue. Inhibition of PDE1 and 4 have been shown to influence detrusor function in several experimental models. [27] [28] [29] [30] [31] Werkstrom et al. 32 showed the presence of the PDE5 isoform in urethral and vascular smooth muscle cells. Furthermore, in the presence of PDE5 inhibitors, smooth muscle relaxation was observed.
In a rat model of bladder outlet obstruction (BOO), chronic treatment with the PDE5-inhibitor vardenafil (10 mg kg -1 per day) resulted in significantly decreased nonvoiding bladder contractions vs placebo. 33 Additional studies have shown PDE-inhibitor dosedependent smooth muscle relaxation in prostatic, urethral, and bladder tissue. Furthermore, vardenafil was shown to inhibit human prostatic stromal proliferation in vivo. 34 Several in vitro studies have examined the effects of stimulation of the NO/cGMP pathway on prostatic smooth muscle tone. A study by Takeda et al. 35 examined the relaxation of isolated strips of prostatic tissue in the presence of inhibitors of NOS during electrical field stimulation. Inhibition of NOS, and subsequent tissue contraction, was seen with L-NAME. Relaxation was induced in the presence of L-arginine, a substrate for NOS. Sodium nitroprusside, an NO donor drug, resulted in significant relaxation of the prostatic tissue. Other NO donor drugs including linsidomine, S-nitrogluthione, and S-nitrosocysteine have been shown to decrease tension in strips of human prostatic tissue from up to 50%. 36, 37 Guh et al. 38 showed that NO donor drugs (sodium nitroprusside) produce anti-proliferative effects on prostatic smooth muscle cells. Direct exposure to PDE5 inhibitors also resulted in a decrease in prostatic tension (20-55%), with a concomitant increase in cGMP levels.
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Animal studies have also shown that the NO/cGMP pathway may be involved in the maintenance of detrusor tone, and is also present in the urothelium and suburothelium. Gillespie et al. [42] [43] [44] found subepithelial neurogenic NOS containing nerves present in bladder interstitial cells. These nerves produce cGMP, facilitating relaxation. Inhibitors of cGMP degradation, namely PDE inhibitors, might, therefore, influence bladder function at this level.
In summary, mediators of the NO pathway, specifically PDEs, may prove to have an important function in prostatic smooth muscle relaxation and overall urinary function. However, further study is required to elucidate the exact effect and mechanism of PDE5-inhibitor action.
AH and the metabolic syndrome
Epidemiologic studies have shown that LUTS may be connected to the metabolic syndrome, which includes type II diabetes, obesity, hyperlipidemia, hypertension, and sedentary lifestyle. These have also all been shown to be risk factors for the development of ED. [45] [46] [47] [48] AH is another component of the metabolic syndrome, involving dysregulation of parasympathetic and sympathetic tone. Penile erection is impaired by increased sympathetic tone. Rat models have shown that manipulation of autonomic activity leads to effects on prostatic growth and differentiation. 49 In aging rats, the development of BPH and ED were promoted by increased autonomic nervous system activity. 50 In addition, hyperlipidemic rats, fed a high fat diet, develop prostatic enlargement, bladder overactivity, and ED. 51 Spontaneously hypertensive rats have been found to develop AH, prostatic hyperplasia, and ED, with detrusor overactivity and increased voiding frequency. 52 A study by Hale et al.
53
showed that brief aggressive treatment of hypertension in these rats results in improvement in ED.
McVary et al. 54 have shown that AH leads to LUTS and subjective voiding complaints. As part of the MTOPs study, the authors examined autonomic nervous system activity in 38 men. Increased sympathetic tone was identified by using tilt table testing. This finding was significantly associated with the degree of LUTS, even after controlling for potential confounders including age, body mass index, abdominal obesity, insulin levels, and physical inactivity. Furthermore, International Prostate Symptom Score (IPSS), BPH impact index (BPH II), and prostate size was strongly associated with AH.
The interaction between parasympathetic and sympathetic tone dictates the level of smooth muscle relaxation in the bladder and prostate. Smooth muscle cells are activated by norepinephrine (NE) from sympathetic nerves, 55 endothelins, 55 and prostaglandin F2-a(PGF2-a) 56 from the endothelium. This ultimately results in a series of events leading to increased intracellular calcium. Through downstream pathways, MLC kinase is activated and phosphorylates the MLC. This allows for its interaction with a-actin, which results in cycling of myosin cross bridges and smooth muscle contraction. PDE5 inhibitors have been shown to increase cGMP levels and decrease prostatic tone in tissue activated by NE. 57 PDE5 inhibitors have also been shown to affect endothelin and PGF2-a levels. 58 Rho-kinase activation Intracellular calcium levels are typically responsible for smooth muscle contraction; however, the Rho-kinase pathway involves muscle contraction independent of calcium concentration. This is thought to occur through regulatory mechanisms that involve calcium sensitizing. 59, 60 Rho A, a G-protein, and its target Rho-kinase have been found to be involved with a-adrenergic (NE) and endothelin-1-stimulated smooth muscle contraction. This occurs through RK inhibition of MLC phosphatase. MLC, therefore, remains activated, and in the presence of MLC kinase, phosphorylated, leads to continued smooth muscle contraction regardless of calcium concentration (Figure 1) . In human endothelial cells, the Rho-kinase pathway has been shown to inhibit activation of endothelial NOS. This could ultimately contribute to decreased smooth muscle relaxation with resultant bladder compliance changes leading to LUTS. Rees et al. 59 suggested that the Rho-kinase pathway regulates smooth muscle tone in conditions involving tonic contraction. Furthermore, inhibitors of Rho-kinase have been shown to decrease human and rat prostatic smooth muscle proliferation and differentiation, and decreased adrenergic-mediated contractions in rat prostates. 61 Several studies have shown increased Rho-kinase activity in the prostates of hypertensive rats, 62 and the detrusor and corpus cavernosum of rabbits with partial BOO. 63, 64 Increased Rho-kinase activity has also been seen in diabetes and vascular smooth muscle in hypertension. 65, 66 In addition, Rho-kinase inhibitors have been shown to alleviate ED in rats, with a potentiated effect with concomitant use of PDE5 inhibitors. 67 Rhokinase affects several factors leading to increased smooth muscle activity, contributing to both LUTS/BPH and ED, and may be the link between these two entities.
Pelvic atherosclerosis
LUTS and ED may be further linked by the presence of diffuse atherosclerosis of the lower urinary tract. 68 Known risk factors for ED and LUTS/BPH overlap, including hypertension, diabetes mellitus, hyperlipidemia, and smoking. Epidemiologic data 69 have shown that the presence of two of the aforementioned risk factors for atherosclerosis results in a statistically significant increase in IPSS vs the presence of one or no risk factors. The alterations of detrusor and corporal smooth muscle induced by pelvic ischemia and hyperlipidemia seem to be very similar. In a rabbit model, chronic ischemia causes smooth muscle atrophy and fibrosis, with decreased bladder compliance. 70 Hyperlipidemia has also been shown to negatively affect bladder compliance. Chronic ischemia also results in prostatic stromal fibrosis, glandular cystic atrophy, and increased smooth muscle contractility, as well as penile fibrosis. 71, 72 These findings may be explained by increased levels of TGF-b1 induced by hypoxia. 70 It may also contribute to decreased elasticity and increased smooth muscle tone in the prostate. 71 In addition, ischemia leads to smooth muscle loss in the penis, bladder, and prostate with varying effects. Penile loss ultimately leads to ED, whereas smooth muscle loss in the bladder leads to fibrosis and decreased compliance and contractility. Loss
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in the prostate would decrease urethra compliance, increase resistance to flow, and ultimately worsen LUTS. 72 Pelvic atherosclerosis and ischemia links all the aforementioned theories, as it is a component of the metabolic syndrome/AH, can decrease NOS expression, and induce Rho-kinase activity 73 ( Figure 2 ).
The effects of PDE5 inhibitors on LUTS
Several studies have examined the role of NO pathway in the treatment of LUTS secondary to BPH through the use of PDE5
inhibitors. An open-labeled study by Sairam et al. 74 examined the effects of sildenafil (VIAGRA) on patients presenting with concomitant ED and LUTS. Of 112 patients included, 20 patients reported LUTS, with 32% experiencing moderate to severe symptoms as measured by the IPSS. After 12 weeks of treatment, an improvement in IPSS and LUTS-specific QOL was reported. All patients with severe LUTS shifted to moderate symptomatology, and 60% of patients with initially moderate symptoms reported mild symptoms at the conclusion of the study. A similar open-labeled study was performed by Mulhall et al. 75 Forty-eight men (mean age 64 ± 11 years) with moderate LUTS (IPSSX10) completed IPSS and IIEF surveys before and after 12 weeks of sildenafil 100 mg treatment (mean number of uses per week 2±0.6). IPSS scores improved in 63%, with 37% experiencing an improvement of 4 þ points in their IPSS. Ying et al. 76 saw similar results with changes in IPSS in 32 men presenting with ED and LUTS treated over 24 weeks with sildenafil.
Kaplan et al. 77 reported the safety and efficacy of the combination of an a-blocker, alfuzosin SR (UROXA-TRAL) and sildenafil compared with monotherapy in patients presenting with LUTS and ED. Sixty-two men (mean age 63.4 years) with untreated LUTS/ED were randomized to three open-labeled treatment arms: alfuzosin (10 mg per day), sildenafil (25 mg per day), or the combination of the two. After 12 weeks of therapy, changes in IPSS, peak urinary flow rate (Qmax), post void residual urine volume, voiding diary, and IIEF were observed. All treatment groups experienced an improvement in IPSS. The mean reduction was greatest in the group receiving combined therapy (À24%) compared with either alfuzosin (À16%) or sildenafil (À17%) alone. Significant improvements in frequency, nocturia, and Qmax were observed in patients receiving either alfuzosin alone or in combination with sildenafil. No significant improvement was shown in the sildenafil monotherapy group. The investigators concluded that the combination of sildenafil and alfuzosin is a safe and effective means to improve sexual function and voiding symptoms in men with concurrent ED and LUTS.
In a randomized, double-blind, placebo-controlled trial, McVary et al. 78 Figure 1 A graphical demonstration of the four proposed theories linking erectile dysfunction (ED) and lower urinary tract symptoms (LUTS). Alternate-pathway theory: Smooth muscle alterations result in increased Rho kinase, which can lead to both ED and LUTS. Autonomichyperactivity theory: Increased autonomic hyperactivity results from increased body mass index (BMI), hyperinsulinemia, increased age and decreased physical activity. The resulting increased sympathetic tone encourages BPH growth, LUTS and vasoconstrictive forces, which result in ED. Theory of pelvic reduction in nitric oxide synthase (NOS) and nitric oxide (NO): Reduction of NOS and NO due to various systemic diseases that also promote ED results in increased smooth muscle cell (SMC) contractile forces at the bladder neck and prostatic urethra. In addition, the reduced NOS/NO results in prostatic SMC proliferation and increased outlet resistance. Both forces worsen the LUTS. Theory of atherosclerosis and pelvic ischemia: The risk factors for ED affect pelvic arterial blood flow, resulting in loss of smooth muscle from the bladder detrusor, with loss of bladder compliance. At the same time, prostate fibrosis increases urethral resistance, resulting in LUTS. A similar process results in smooth muscle loss in the penis with resultant ED.
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and BPH with LUTS (IPSSX12). Patients received 50 mg dosage at bedtime or 1 h before sexual activity for 2 weeks, followed by 100 mg sildenafil daily for 10 weeks. Primary outcomes included changes in erectile function measured by IIEF, and secondary outcomes included changes in IPSS (QOL, BPH II, and Qmax). A significant reduction in IPSS was found compared with placebo (À6.32 vs À1.93 points). Patients with severe LUTS experienced a greater reduction than those with moderate LUTS (À8.6 ± À2.4 vs -3.6 ± -1.7). Significant improvements were also noted in QOL and BPH II; however, no significant change in Qmax was seen.
Tadalafil (CIALIS) was also investigated for the treatment of moderate to severe LUTS secondary to BPH in a randomized, double-blind, placebo-controlled study involving 281 men by McVary et al. 34 Patients were stratified by baseline IPSS (moderate: 13-19, severe: 20-35), geographic region, and earlier therapy. After a 4-week placebo run-in phase to establish baseline IPSS and uroflowmetry values, patients were randomized to either treatment with tadalafil (5 mg for 6 weeks subsequently increased to 20 mg for 6 weeks) or placebo for 12 weeks. Efficacy was established through change in IPSS at 6 and 12 weeks of therapy. Secondary end points included changes in IPSS QOL index, BPH II, uroflowmetry values (Qmax), and the LUTS Global Assessment Question (GAQ; 'Has the treatment you have been taking since your last visit improved your urinary symptoms?'). At both 6 and 12 weeks of treatment, the tadalafil treatment group experienced improvement in LUTS with significant decrease in IPSS compared with placebo: À2.8 vs À1.2 (6 weeks) and À3.8 vs À1.7 (12 weeks). Sub-analysis of irritative and obstructive voiding symptoms also showed significant improvements in the treatment arm. It was found, however, that there was no change in Qmax compared with placebo.
Stief et al. 79 examined vardenafil (LEVITRA) for the treatment of LUTS in a multi-center, randomized, double-blind, placebo-controlled trial. A group of 222 men with LUTS (IPSSX12) were randomized to either vardenafil (10 mg twice daily) or placebo, and studied over an 8-week period. Efficacy was assessed by changes in IPSS, UROLIFE QOL 9, Qmax, and PVR parameters. After treatment, a significant reduction of 5.9 points on the IPSS was seen in the treatment group vs 3.6 points seen with placebo. Sub-scores for storage and voiding symptoms also showed a significant improvement with treatment, as did UROLIFE QOL. However, no significant change was noted in either PVR or Qmax.
Roehrborn et al. 80 performed a dose-finding study using tadalafil for LUTS. The authors examined 1058 men in a randomized, double-blind, placebo-controlled, Figure 2 Smooth muscle relaxation and contraction is typically obtained through a calcium-dependent mechanism of action, whereas the alternate pathway via Rho-kinase activation is calcium independent. Recent work has identified RhoA, a small G-protein, and its downstream target, Rho-kinase, as possible mediators of the alpha-adrenergic (norepinephrine) and endothelial (ET-1) triggered smooth muscle contraction. This is thought to occur by way of Rho-kinase inhibition of MLC phosphatase. MLC phosphatase de-phosphorylates MLC, stopping MLC from interacting with alpha-actin, and promoting smooth muscle relaxation and erection. Owing to inhibition of MLC phosphatase by Rho-kinase, there will be more active (phosphorylated) MLC available at the same level of MLC kinase activity (without requiring an increase in cytosolic Ca), effectively ''sensitizing'' the smooth muscle, and so contributing to the tonic phase of agonist-induced penile smooth muscle contraction and flaccidity. Intracellular calcium levels are typically responsible for smooth muscle contraction; however, the Rho-kinase pathway involves muscle contraction independent of calcium concentration. This is thought to occur through regulatory mechanisms that involve calcium sensitization. 58, 59 Rho A, a G-protein, and its target Rho-kinase have been found to be involved in a-adrenergic (NE) and endothelin-1 (ET-1) stimulated smooth muscle contraction. This occurs through RK inhibition of MLC phosphatase. MLC therefore remains activated, and, in the presence of MLC kinase, phosphorylated, leading to continued smooth muscle contraction, regardless of calcium concentration.
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S Mouli and KT McVary parallel group study. The patients were assigned to placebo or one of four different tadalafil dosing regimens (2.5, 5, 10, or 20 mg daily). Participating patients initially presented with an IPSSX11. After using a 4-week singleblind placebo run-in phase, men were stratified by baseline IPSS (o20 or X20), uroflowmetry parameters, and ED history (o3 mos, or X3 mos). End points assessed included IPSS, irritative and obstructive subscores, QOL assessment, BPH II, Qmax, and LUTS GAQ. In the 5-mg treatment group, a statistically significant reduction in IPSS was observed, with a decrease of 4.9 vs 1.8 in placebo. IPSS QOL, BPH II, and LUTS GAQ all significantly improved at this dosage level. Urinary flow and Qmax were not affected by any dosage level in comparison with placebo. It was noted that when increasing the tadalafil dosage beyond 5 mg produced similar improvements in IPSS, it was at the cost of a higher incidence of adverse effects.
All the aforementioned clinical studies show significant improvement in IPSS after PDE5-inhibitor therapy compared with placebo. These improvements are in line with the results seen in earlier studies involving ablocker therapy. A study by Roehrborn 81 showed that when following treatment with 10 mg alfuzosin (12 weeks), the IPSS was significantly decreased by 3.8 vs 1.7 points in placebo. Further direct comparison to a-blocking agents is necessary.
None of these studies have shown an effect on urinary flow rate (Qmax) after PDE5-inhibitor treatment. This may be explained by PDE5 inhibitors primarily affecting detrusor activity rather than BOO itself. A study by Gacci et al. 82 in men with neurogenic bladders secondary to spinal cord injury showed that open-labeled vardenafil treatment resulted in significant improvements in maximum detrussor pressure, total capacity, and volumetriggered bladder spasms. Thus, PDE5 inhibitors may act at an alternative site of action, separate from a-blockers.
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Their effects may be secondary to relaxation of smooth muscle present in the prostate, urethra, and bladder neck, as well as their vascular supply. [84] [85] [86] [87] In vitro studies have also shown that NO donor drugs and PDE5 inhibitors may stimulate anti-proliferative or apoptotic effects in the prostate, improved pelvic blood flow, and effects on afferent nerves from the prostate or bladder, resulting in their improvement of LUTS symptoms. 88, 89 A recent study by Dmochowski et al. 90 examined LUTS and urodynamic parameters in 200 men (baseline IPSSX13) randomized to tadalafil (20 mg) treatment or placebo for 12 weeks. In addition, BOO index was examined after treatment. Although no difference was noted in urodynamic parameters after treatment (including BOO index), IPSS improved significantly in the treatment group compared with placebo. Furthermore, at the conclusion of the study, the proportion of obstructed patients in the treatment group decreased, whereas the proportion in the placebo group increased. Thus, the exact mechanism by which PDE5 inhibitors exert their effect on urinary symptoms is not completely understood.
Discussion
Both ED and LUTS secondary to BPH are found to be increasingly prevalent as men age. Several large epidemiologic studies have shown an association between LUTS and ED independent of age and other comorbidities, implying a causal relationship. Few studies have examined a temporal association, and further research is required. 91, 92 Four possible pathophysiologic mechanisms have been described and may explain the role of PDE5-inhibitor therapy in LUTS. PDE5 inhibitors facilitate smooth muscle relaxation through the NO/ cGMP pathway, with effects in the bladder, prostate, and urethra. This theory is supported by the findings of multiple large trials showing significant improvement in LUTS after PDE5-inhibitors therapy. In addition, PDE5 inhibitors have been shown to counter AH (which is mediated through increased second messengers NE and endothelin levels). Rho-kinase's effects are mediated in part by these same second messengers, and it too can be affected by PDE5 inhibitors. Pelvic atherosclerosis and ischemia tie together all these concepts. In its presence, Rho-kinase is upregulated, NOS is downregulated, and AH is induced as a component of the metabolic syndrome.
The results of these studies imply that PDE5 inhibitors predominantly improve storage symptoms (IPSS) rather than voiding symptoms (Qmax). However, the exact mechanism of action is not well understood. Earlier studies have shown increased LUTS in aging men and women, pointing to a source other than the prostate causing these symptoms. 93 Experimental models, in human and rat tissue, have shown that PDE5 inhibitors decrease nonvoiding bladder contractions. 94, 83 In addition, PDE5 inhibitors have been shown to improve urodynamic parameters in SCI patients.
82 PDE5 inhibitors offer an opportunity to treat ED and LUTS concurrently. Furthermore, there may be a role of PDE5 inhibitors in the treatment of LUTS in men without ED and in women.
